There are plenty of growth stocks trading at obscenely high valuations right now. Part of the reason for that is the current enthusiasm for all things artificial intelligence (AI)-related. Some of those...
Markets sent a clear message Friday following President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services (HHS). Vaccine stocks took a nosedive,...
Robert F. Kennedy Jr., recently named President-elect Donald Trump’s nominee for Health and Human Services Secretary, has pledged sweeping reforms at the U.S. Food and Drug Administration (FDA). Kennedy,...
The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY announcing their results. AbbVie’s ABBV schizophrenia candidate, added from a recent...
AstraZeneca just released some encouraging data about its weight loss drug candidates.
AZN earnings call for the period ending September 30, 2024.
AstraZeneca’s AZN third-quarter 2024 core earnings of $1.04 per American depositary share (ADS) beat the Zacks Consensus Estimate of $1.01 per share. Core earnings of $2.08 per share fell 20% year over...
Monday U.S. Featured Earnings Monday.Com Ltd (NASDAQ: MNDY) (Q3) EPS of four cents, compared ...
Key TakeawaysZacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture appears to brighten in 2025.The healthcare company has beaten earnings estimates in...
Investors in AstraZeneca PLC AZN need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2025 $35.00 Call had some of the highest implied volatility...